| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Models, Statistical | 28 | 2022 | 5079 | 2.660 |
Why?
|
| Biometry | 18 | 2019 | 563 | 2.620 |
Why?
|
| Survival Analysis | 27 | 2022 | 10090 | 2.020 |
Why?
|
| Alzheimer Disease | 44 | 2024 | 8601 | 1.730 |
Why?
|
| Likelihood Functions | 16 | 2019 | 992 | 1.690 |
Why?
|
| Research Design | 13 | 2019 | 6180 | 1.340 |
Why?
|
| Proportional Hazards Models | 25 | 2024 | 12463 | 1.280 |
Why?
|
| Computer Simulation | 25 | 2023 | 6241 | 1.160 |
Why?
|
| Data Interpretation, Statistical | 15 | 2019 | 2691 | 1.150 |
Why?
|
| Clinical Trials as Topic | 15 | 2024 | 8002 | 1.070 |
Why?
|
| Statistics, Nonparametric | 6 | 2016 | 2850 | 0.970 |
Why?
|
| Comparative Genomic Hybridization | 5 | 2016 | 473 | 0.900 |
Why?
|
| Biostatistics | 2 | 2015 | 164 | 0.890 |
Why?
|
| Neurofibrillary Tangles | 6 | 2022 | 457 | 0.830 |
Why?
|
| Amyloid beta-Peptides | 23 | 2023 | 3839 | 0.770 |
Why?
|
| Plaque, Amyloid | 11 | 2020 | 760 | 0.760 |
Why?
|
| Oligodendroglioma | 13 | 2010 | 279 | 0.700 |
Why?
|
| Randomized Controlled Trials as Topic | 12 | 2020 | 10212 | 0.690 |
Why?
|
| Disease Progression | 25 | 2024 | 13510 | 0.670 |
Why?
|
| Bayes Theorem | 3 | 2017 | 2330 | 0.590 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2013 | 857 | 0.570 |
Why?
|
| Accidents, Traffic | 2 | 2013 | 816 | 0.570 |
Why?
|
| Parkinson Disease | 8 | 2024 | 2877 | 0.570 |
Why?
|
| Facial Paralysis | 1 | 2021 | 346 | 0.560 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 3 | 2013 | 556 | 0.550 |
Why?
|
| DNA Copy Number Variations | 4 | 2016 | 2020 | 0.540 |
Why?
|
| tau Proteins | 9 | 2022 | 2095 | 0.530 |
Why?
|
| Humans | 241 | 2024 | 761572 | 0.520 |
Why?
|
| Apolipoprotein E4 | 6 | 2022 | 709 | 0.510 |
Why?
|
| Wounds and Injuries | 3 | 2013 | 2491 | 0.510 |
Why?
|
| Brain Neoplasms | 26 | 2018 | 9031 | 0.510 |
Why?
|
| Statistics as Topic | 3 | 2017 | 2358 | 0.500 |
Why?
|
| Epidemics | 1 | 2020 | 512 | 0.480 |
Why?
|
| Regression Analysis | 9 | 2019 | 6344 | 0.470 |
Why?
|
| Cerebral Amyloid Angiopathy | 10 | 2015 | 895 | 0.470 |
Why?
|
| Mortality | 2 | 2016 | 2901 | 0.460 |
Why?
|
| Apolipoproteins E | 9 | 2022 | 1444 | 0.460 |
Why?
|
| Brain | 29 | 2024 | 27120 | 0.440 |
Why?
|
| Specimen Handling | 4 | 2012 | 702 | 0.440 |
Why?
|
| Case-Control Studies | 12 | 2019 | 22176 | 0.440 |
Why?
|
| Research Subjects | 1 | 2015 | 249 | 0.430 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2015 | 257 | 0.430 |
Why?
|
| Sample Size | 6 | 2014 | 841 | 0.430 |
Why?
|
| Probability | 6 | 2022 | 2477 | 0.420 |
Why?
|
| Propylene Glycols | 1 | 2013 | 91 | 0.420 |
Why?
|
| Controlled Clinical Trials as Topic | 3 | 1997 | 186 | 0.400 |
Why?
|
| Acute Kidney Injury | 9 | 2017 | 1924 | 0.400 |
Why?
|
| Glioma | 9 | 2012 | 3455 | 0.390 |
Why?
|
| Glioblastoma | 13 | 2018 | 3482 | 0.390 |
Why?
|
| Rural Health | 1 | 2013 | 296 | 0.390 |
Why?
|
| Age of Onset | 9 | 2024 | 3306 | 0.390 |
Why?
|
| Longitudinal Studies | 14 | 2024 | 14607 | 0.380 |
Why?
|
| Markov Chains | 4 | 2012 | 966 | 0.370 |
Why?
|
| Algorithms | 13 | 2018 | 14032 | 0.370 |
Why?
|
| Logistic Models | 10 | 2019 | 13255 | 0.370 |
Why?
|
| Lectins | 3 | 2012 | 491 | 0.370 |
Why?
|
| Genome, Human | 3 | 2016 | 4425 | 0.370 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 787 | 0.370 |
Why?
|
| Adipokines | 3 | 2012 | 310 | 0.370 |
Why?
|
| Neurosciences | 1 | 2015 | 367 | 0.370 |
Why?
|
| Aged | 99 | 2024 | 169310 | 0.360 |
Why?
|
| Sphingosine | 1 | 2013 | 308 | 0.360 |
Why?
|
| Models, Genetic | 5 | 2006 | 3442 | 0.360 |
Why?
|
| Cluster Analysis | 3 | 2009 | 2707 | 0.350 |
Why?
|
| Linear Models | 3 | 2018 | 5872 | 0.350 |
Why?
|
| Aged, 80 and over | 59 | 2024 | 58986 | 0.340 |
Why?
|
| Dementia | 6 | 2024 | 2689 | 0.340 |
Why?
|
| Rural Health Services | 1 | 2013 | 384 | 0.340 |
Why?
|
| Homicide | 1 | 2012 | 294 | 0.330 |
Why?
|
| Diagnostic Errors | 4 | 2013 | 1265 | 0.330 |
Why?
|
| Amyloid | 5 | 2016 | 841 | 0.330 |
Why?
|
| Vaccination | 1 | 2021 | 3384 | 0.320 |
Why?
|
| Amyloidosis | 5 | 2019 | 817 | 0.310 |
Why?
|
| Genomics | 4 | 2022 | 5821 | 0.310 |
Why?
|
| Chromosomes, Human, Pair 1 | 9 | 2012 | 638 | 0.310 |
Why?
|
| Placebos | 1 | 2013 | 1667 | 0.310 |
Why?
|
| Histology | 1 | 2007 | 16 | 0.300 |
Why?
|
| Apolipoprotein E2 | 2 | 2021 | 135 | 0.300 |
Why?
|
| Neurology | 1 | 2015 | 780 | 0.290 |
Why?
|
| Male | 121 | 2024 | 360842 | 0.280 |
Why?
|
| Genetic Predisposition to Disease | 11 | 2018 | 17904 | 0.280 |
Why?
|
| Female | 125 | 2024 | 392686 | 0.280 |
Why?
|
| Trauma Centers | 1 | 2012 | 937 | 0.280 |
Why?
|
| Monte Carlo Method | 6 | 2014 | 1258 | 0.270 |
Why?
|
| Twin Studies as Topic | 1 | 2006 | 103 | 0.260 |
Why?
|
| Stroke | 8 | 2018 | 9758 | 0.260 |
Why?
|
| Neurilemmoma | 2 | 2008 | 526 | 0.250 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2007 | 219 | 0.250 |
Why?
|
| Numerical Analysis, Computer-Assisted | 2 | 2002 | 119 | 0.250 |
Why?
|
| Positron-Emission Tomography | 11 | 2023 | 6485 | 0.250 |
Why?
|
| Pneumonia | 2 | 2013 | 2143 | 0.240 |
Why?
|
| Calcineurin | 2 | 2018 | 229 | 0.240 |
Why?
|
| Emergency Medical Services | 2 | 2013 | 1923 | 0.240 |
Why?
|
| AIDS-Related Opportunistic Infections | 4 | 2005 | 662 | 0.240 |
Why?
|
| Pure Autonomic Failure | 1 | 2024 | 16 | 0.240 |
Why?
|
| Mucolipidoses | 2 | 2015 | 82 | 0.240 |
Why?
|
| Cross Infection | 1 | 2013 | 1422 | 0.230 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2006 | 1302 | 0.230 |
Why?
|
| Follow-Up Studies | 11 | 2023 | 39107 | 0.230 |
Why?
|
| Middle Aged | 80 | 2024 | 220920 | 0.230 |
Why?
|
| Immunosuppressive Agents | 3 | 2013 | 4176 | 0.220 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2006 | 629 | 0.220 |
Why?
|
| Central Nervous System Neoplasms | 5 | 2013 | 916 | 0.220 |
Why?
|
| Multiple System Atrophy | 2 | 2024 | 130 | 0.220 |
Why?
|
| Immunohistochemistry | 16 | 2018 | 11076 | 0.220 |
Why?
|
| Acquired Immunodeficiency Syndrome | 8 | 2013 | 2199 | 0.210 |
Why?
|
| Chromosomes, Human, Pair 19 | 6 | 2009 | 350 | 0.210 |
Why?
|
| Genotype | 9 | 2021 | 12990 | 0.210 |
Why?
|
| Cognition | 7 | 2024 | 6992 | 0.210 |
Why?
|
| Mycosis Fungoides | 1 | 2024 | 170 | 0.210 |
Why?
|
| Lymphoma | 5 | 2013 | 1901 | 0.200 |
Why?
|
| Family Health | 1 | 2007 | 1257 | 0.200 |
Why?
|
| Siblings | 1 | 2006 | 825 | 0.200 |
Why?
|
| Dermatology | 2 | 2023 | 918 | 0.200 |
Why?
|
| Meningeal Neoplasms | 4 | 2013 | 1248 | 0.200 |
Why?
|
| Learning Curve | 1 | 2023 | 230 | 0.200 |
Why?
|
| Physical Fitness | 1 | 2006 | 743 | 0.190 |
Why?
|
| Creatinine | 3 | 2013 | 1899 | 0.190 |
Why?
|
| Neuropsychological Tests | 9 | 2022 | 7054 | 0.190 |
Why?
|
| Genetic Markers | 5 | 2008 | 2601 | 0.190 |
Why?
|
| Fallopian Tubes | 2 | 2012 | 178 | 0.190 |
Why?
|
| Aniline Compounds | 6 | 2017 | 1069 | 0.190 |
Why?
|
| Hemophilia A | 5 | 2003 | 360 | 0.190 |
Why?
|
| Sequence Analysis, DNA | 2 | 2013 | 4740 | 0.190 |
Why?
|
| Meningioma | 4 | 2012 | 1218 | 0.190 |
Why?
|
| Suicide | 1 | 2012 | 1601 | 0.190 |
Why?
|
| Cognition Disorders | 4 | 2016 | 3980 | 0.180 |
Why?
|
| Mice, Transgenic | 17 | 2019 | 9541 | 0.180 |
Why?
|
| Genetic Linkage | 1 | 2006 | 2341 | 0.180 |
Why?
|
| Optic Nerve | 2 | 2015 | 572 | 0.180 |
Why?
|
| Virus Latency | 2 | 2019 | 363 | 0.180 |
Why?
|
| Odds Ratio | 5 | 2018 | 9646 | 0.180 |
Why?
|
| DNA, Neoplasm | 5 | 2009 | 1745 | 0.180 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2024 | 178 | 0.180 |
Why?
|
| Adult | 60 | 2024 | 221203 | 0.180 |
Why?
|
| Platelet Function Tests | 1 | 2022 | 271 | 0.180 |
Why?
|
| Tauopathies | 2 | 2014 | 320 | 0.170 |
Why?
|
| Gene Expression Profiling | 8 | 2022 | 9420 | 0.170 |
Why?
|
| Time Factors | 16 | 2019 | 39970 | 0.170 |
Why?
|
| Molecular Diagnostic Techniques | 3 | 2012 | 610 | 0.170 |
Why?
|
| Prognosis | 26 | 2024 | 29629 | 0.170 |
Why?
|
| Neurons | 9 | 2019 | 9463 | 0.170 |
Why?
|
| Confidence Intervals | 6 | 2018 | 2927 | 0.170 |
Why?
|
| Anterior Cruciate Ligament | 1 | 2023 | 423 | 0.170 |
Why?
|
| Synapses | 4 | 2019 | 1769 | 0.170 |
Why?
|
| Paraffin Embedding | 3 | 2012 | 302 | 0.170 |
Why?
|
| Neoplasms | 6 | 2019 | 22173 | 0.170 |
Why?
|
| Cerebral Hemorrhage | 4 | 2022 | 2656 | 0.170 |
Why?
|
| Twins | 1 | 2001 | 339 | 0.160 |
Why?
|
| Esophageal Neoplasms | 2 | 2020 | 1654 | 0.160 |
Why?
|
| Retrospective Studies | 30 | 2024 | 80646 | 0.160 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2015 | 632 | 0.160 |
Why?
|
| Family | 4 | 2014 | 3194 | 0.160 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2018 | 1164 | 0.160 |
Why?
|
| Software | 5 | 2018 | 4434 | 0.160 |
Why?
|
| Chromosomes, Artificial, Bacterial | 2 | 2010 | 123 | 0.160 |
Why?
|
| Limit of Detection | 1 | 2019 | 273 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2015 | 6484 | 0.160 |
Why?
|
| Cellulitis | 1 | 2020 | 209 | 0.150 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2018 | 42 | 0.150 |
Why?
|
| Intracranial Hemorrhages | 3 | 2018 | 822 | 0.150 |
Why?
|
| Visual Cortex | 2 | 2019 | 1108 | 0.150 |
Why?
|
| Autopsy | 3 | 2017 | 1009 | 0.150 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2018 | 69 | 0.150 |
Why?
|
| Astrocytes | 5 | 2015 | 1346 | 0.150 |
Why?
|
| Weights and Measures | 2 | 2008 | 41 | 0.150 |
Why?
|
| Appointments and Schedules | 1 | 2002 | 443 | 0.150 |
Why?
|
| Hypotension, Orthostatic | 1 | 2021 | 258 | 0.150 |
Why?
|
| Healthcare Disparities | 1 | 2013 | 3358 | 0.150 |
Why?
|
| Chromosome Aberrations | 4 | 2012 | 1768 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2014 | 9280 | 0.150 |
Why?
|
| Cohort Studies | 20 | 2024 | 41493 | 0.150 |
Why?
|
| Gene Dosage | 3 | 2011 | 1218 | 0.150 |
Why?
|
| Brain Ischemia | 3 | 2018 | 3049 | 0.140 |
Why?
|
| Cystadenocarcinoma, Serous | 2 | 2012 | 478 | 0.140 |
Why?
|
| Rheumatology | 1 | 2023 | 615 | 0.140 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2021 | 445 | 0.140 |
Why?
|
| Hydroxychloroquine | 1 | 2021 | 426 | 0.140 |
Why?
|
| Microglia | 4 | 2015 | 1361 | 0.140 |
Why?
|
| Veterans | 2 | 2024 | 2649 | 0.140 |
Why?
|
| Propensity Score | 2 | 2021 | 1913 | 0.140 |
Why?
|
| Alopecia | 1 | 2021 | 412 | 0.140 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2018 | 214 | 0.140 |
Why?
|
| Piperidines | 2 | 2023 | 1656 | 0.140 |
Why?
|
| Aging | 6 | 2019 | 8711 | 0.140 |
Why?
|
| Skin Neoplasms | 3 | 2024 | 5821 | 0.140 |
Why?
|
| Methylphenidate | 1 | 2020 | 488 | 0.130 |
Why?
|
| Amyloidogenic Proteins | 1 | 2017 | 151 | 0.130 |
Why?
|
| Olfactory Perception | 1 | 2016 | 65 | 0.130 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2016 | 3778 | 0.130 |
Why?
|
| Medical Staff, Hospital | 1 | 2020 | 601 | 0.130 |
Why?
|
| Lewy Body Disease | 2 | 2024 | 252 | 0.130 |
Why?
|
| Calibration | 1 | 2018 | 818 | 0.130 |
Why?
|
| Bioethics | 1 | 1997 | 117 | 0.130 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2018 | 278 | 0.130 |
Why?
|
| Polymorphism, Genetic | 4 | 2012 | 4243 | 0.130 |
Why?
|
| Antigens, CD19 | 1 | 1999 | 424 | 0.130 |
Why?
|
| Medical Oncology | 1 | 2007 | 2321 | 0.130 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 5440 | 0.130 |
Why?
|
| Treatment Failure | 1 | 2002 | 2644 | 0.130 |
Why?
|
| Memory | 2 | 2023 | 2193 | 0.130 |
Why?
|
| Epidemiologic Methods | 1 | 2000 | 1336 | 0.130 |
Why?
|
| Linkage Disequilibrium | 1 | 2000 | 1998 | 0.130 |
Why?
|
| Vitamin D | 2 | 2019 | 3303 | 0.130 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 621 | 0.130 |
Why?
|
| 2,3-Diphosphoglycerate | 1 | 2014 | 13 | 0.120 |
Why?
|
| Health | 1 | 2018 | 398 | 0.120 |
Why?
|
| Prospective Studies | 18 | 2024 | 54426 | 0.120 |
Why?
|
| Cicatrix | 1 | 2021 | 798 | 0.120 |
Why?
|
| Nerve Degeneration | 2 | 2012 | 748 | 0.120 |
Why?
|
| Retinal Dystrophies | 1 | 2015 | 65 | 0.120 |
Why?
|
| Alleles | 5 | 2015 | 6864 | 0.120 |
Why?
|
| Chest Pain | 1 | 2022 | 1091 | 0.120 |
Why?
|
| Malpractice | 1 | 2020 | 556 | 0.120 |
Why?
|
| PAX2 Transcription Factor | 2 | 2012 | 86 | 0.120 |
Why?
|
| Multivariate Analysis | 5 | 2018 | 12059 | 0.120 |
Why?
|
| Metformin | 1 | 2022 | 906 | 0.120 |
Why?
|
| Hospitals | 2 | 2020 | 3882 | 0.120 |
Why?
|
| Hospital Mortality | 4 | 2022 | 5293 | 0.120 |
Why?
|
| HIV Infections | 11 | 2019 | 17352 | 0.120 |
Why?
|
| Adolescent | 26 | 2024 | 88324 | 0.120 |
Why?
|
| Renal Replacement Therapy | 2 | 2014 | 282 | 0.120 |
Why?
|
| NFATC Transcription Factors | 2 | 2018 | 389 | 0.120 |
Why?
|
| Knee Joint | 1 | 2023 | 1676 | 0.120 |
Why?
|
| Memory Disorders | 2 | 2023 | 1199 | 0.120 |
Why?
|
| AIDS-Related Complex | 1 | 2014 | 107 | 0.120 |
Why?
|
| Dental Impression Materials | 1 | 2014 | 37 | 0.120 |
Why?
|
| Gliosis | 2 | 2014 | 245 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2018 | 15936 | 0.120 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2007 | 1374 | 0.110 |
Why?
|
| Risk | 5 | 2023 | 9610 | 0.110 |
Why?
|
| Microvessels | 1 | 2018 | 577 | 0.110 |
Why?
|
| Mosaicism | 3 | 2012 | 475 | 0.110 |
Why?
|
| Hypophosphatemia | 1 | 2014 | 92 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 15 | 2024 | 36429 | 0.110 |
Why?
|
| Twins, Monozygotic | 2 | 2009 | 470 | 0.110 |
Why?
|
| Renal Dialysis | 4 | 2016 | 1796 | 0.110 |
Why?
|
| Treatment Outcome | 19 | 2024 | 64684 | 0.110 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 3 | 2015 | 267 | 0.110 |
Why?
|
| Young Adult | 17 | 2024 | 59255 | 0.110 |
Why?
|
| Home Care Services | 1 | 2020 | 648 | 0.110 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 15501 | 0.110 |
Why?
|
| Dental Impression Technique | 1 | 2014 | 59 | 0.110 |
Why?
|
| Carbolines | 1 | 2015 | 296 | 0.110 |
Why?
|
| DNA, Mitochondrial | 2 | 2012 | 865 | 0.110 |
Why?
|
| In Situ Hybridization, Fluorescence | 6 | 2012 | 2510 | 0.110 |
Why?
|
| Prevalence | 5 | 2024 | 15732 | 0.110 |
Why?
|
| Chromosome Deletion | 3 | 2009 | 1386 | 0.110 |
Why?
|
| United States | 12 | 2024 | 72335 | 0.110 |
Why?
|
| Genetic Association Studies | 2 | 2014 | 2735 | 0.110 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2016 | 411 | 0.110 |
Why?
|
| Multiple Sclerosis | 2 | 2024 | 3220 | 0.110 |
Why?
|
| Caffeine | 1 | 2018 | 700 | 0.110 |
Why?
|
| Nervous System Diseases | 2 | 2014 | 1667 | 0.110 |
Why?
|
| Amyloid beta-Protein Precursor | 4 | 2019 | 1111 | 0.110 |
Why?
|
| Models, Biological | 5 | 2020 | 9469 | 0.110 |
Why?
|
| Dendrites | 2 | 2012 | 475 | 0.110 |
Why?
|
| Immunoglobulin Heavy Chains | 2 | 2006 | 647 | 0.110 |
Why?
|
| Disease Models, Animal | 12 | 2019 | 18253 | 0.110 |
Why?
|
| Antibodies | 2 | 2014 | 2418 | 0.100 |
Why?
|
| Receptors, Virus | 2 | 2014 | 640 | 0.100 |
Why?
|
| Image Processing, Computer-Assisted | 7 | 2017 | 9002 | 0.100 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2008 | 646 | 0.100 |
Why?
|
| Dendritic Spines | 2 | 2013 | 243 | 0.100 |
Why?
|
| Chi-Square Distribution | 1 | 1999 | 3416 | 0.100 |
Why?
|
| Sensitivity and Specificity | 8 | 2017 | 14666 | 0.100 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2013 | 146 | 0.100 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2018 | 895 | 0.100 |
Why?
|
| Lymphocytes | 1 | 2000 | 2612 | 0.100 |
Why?
|
| Calcium Signaling | 1 | 2017 | 733 | 0.100 |
Why?
|
| Adenovirus Infections, Human | 1 | 2013 | 73 | 0.100 |
Why?
|
| HIV | 1 | 2019 | 1582 | 0.100 |
Why?
|
| Dental Prosthesis Design | 1 | 2014 | 264 | 0.100 |
Why?
|
| Cross-Over Studies | 1 | 2018 | 2079 | 0.100 |
Why?
|
| Agglutinins | 2 | 2002 | 28 | 0.100 |
Why?
|
| Computer-Aided Design | 1 | 2014 | 300 | 0.100 |
Why?
|
| Skin Diseases | 1 | 2021 | 1094 | 0.100 |
Why?
|
| src-Family Kinases | 1 | 2014 | 535 | 0.100 |
Why?
|
| Adenocarcinoma | 2 | 2020 | 6346 | 0.100 |
Why?
|
| Extracellular Fluid | 1 | 2013 | 165 | 0.100 |
Why?
|
| Risk Factors | 19 | 2024 | 74213 | 0.100 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 2 | 2011 | 368 | 0.100 |
Why?
|
| Antidepressive Agents | 1 | 2024 | 2897 | 0.100 |
Why?
|
| Corpus Striatum | 1 | 2018 | 1235 | 0.100 |
Why?
|
| Cytomegalovirus | 3 | 2002 | 756 | 0.100 |
Why?
|
| Boston | 4 | 2023 | 9326 | 0.100 |
Why?
|
| Glomerular Filtration Rate | 2 | 2018 | 2177 | 0.100 |
Why?
|
| Autoimmune Diseases | 1 | 2024 | 2244 | 0.100 |
Why?
|
| Patient Compliance | 1 | 2002 | 2690 | 0.100 |
Why?
|
| Formaldehyde | 2 | 2010 | 358 | 0.100 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2017 | 2010 | 0.090 |
Why?
|
| Membrane Glycoproteins | 3 | 2014 | 3701 | 0.090 |
Why?
|
| Pyrimidines | 1 | 2023 | 3028 | 0.090 |
Why?
|
| CD4 Lymphocyte Count | 4 | 2002 | 2571 | 0.090 |
Why?
|
| Loss of Heterozygosity | 4 | 2006 | 662 | 0.090 |
Why?
|
| Pathology, Surgical | 1 | 2012 | 151 | 0.090 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2021 | 1473 | 0.090 |
Why?
|
| Methotrexate | 3 | 2008 | 1719 | 0.090 |
Why?
|
| Thiazoles | 5 | 2017 | 1517 | 0.090 |
Why?
|
| Adenoviruses, Human | 1 | 2013 | 255 | 0.090 |
Why?
|
| Fixatives | 1 | 2010 | 90 | 0.090 |
Why?
|
| Mutation | 12 | 2022 | 30054 | 0.090 |
Why?
|
| Neuroglia | 4 | 2019 | 956 | 0.090 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 2016 | 1496 | 0.090 |
Why?
|
| Vitamins | 1 | 2019 | 1635 | 0.090 |
Why?
|
| Mice | 23 | 2019 | 81533 | 0.090 |
Why?
|
| Reproducibility of Results | 8 | 2023 | 20099 | 0.090 |
Why?
|
| Bacterial Infections | 1 | 1999 | 1391 | 0.090 |
Why?
|
| Pneumonia, Pneumocystis | 2 | 2005 | 242 | 0.090 |
Why?
|
| Predictive Value of Tests | 12 | 2012 | 15266 | 0.090 |
Why?
|
| Disability Evaluation | 2 | 2008 | 1836 | 0.090 |
Why?
|
| Neoplasm Staging | 2 | 2024 | 11121 | 0.090 |
Why?
|
| Epistasis, Genetic | 1 | 2012 | 352 | 0.090 |
Why?
|
| Animals | 27 | 2019 | 168467 | 0.090 |
Why?
|
| Cerebral Cortex | 2 | 2017 | 5779 | 0.090 |
Why?
|
| Influenza, Human | 1 | 2021 | 1521 | 0.090 |
Why?
|
| Mycobacterium avium Complex | 2 | 1999 | 60 | 0.090 |
Why?
|
| Survival Rate | 10 | 2020 | 12725 | 0.090 |
Why?
|
| Regeneration | 1 | 2019 | 1512 | 0.090 |
Why?
|
| Hippocampus | 3 | 2018 | 3766 | 0.080 |
Why?
|
| New York City | 2 | 2023 | 731 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 10 | 4 | 2005 | 277 | 0.080 |
Why?
|
| Cytomegalovirus Infections | 3 | 2002 | 831 | 0.080 |
Why?
|
| Pelvic Neoplasms | 1 | 2011 | 247 | 0.080 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 2 | 1999 | 76 | 0.080 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2018 | 617 | 0.080 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2012 | 328 | 0.080 |
Why?
|
| Nitriles | 1 | 2014 | 971 | 0.080 |
Why?
|
| Salvage Therapy | 2 | 2007 | 1264 | 0.080 |
Why?
|
| Myasthenia Gravis | 1 | 2012 | 214 | 0.080 |
Why?
|
| Cytoskeletal Proteins | 2 | 2012 | 1342 | 0.080 |
Why?
|
| Comorbidity | 1 | 2024 | 10508 | 0.080 |
Why?
|
| Quinolines | 1 | 2014 | 764 | 0.080 |
Why?
|
| Hematoma | 1 | 2014 | 767 | 0.080 |
Why?
|
| Genome, Viral | 1 | 2013 | 667 | 0.080 |
Why?
|
| Injury Severity Score | 1 | 2012 | 1045 | 0.080 |
Why?
|
| Hydatidiform Mole | 1 | 2011 | 255 | 0.080 |
Why?
|
| Ear, External | 1 | 2009 | 165 | 0.080 |
Why?
|
| Neurologic Examination | 1 | 2012 | 916 | 0.080 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2008 | 60 | 0.080 |
Why?
|
| Cerebrovascular Disorders | 1 | 2015 | 1474 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 5 | 2007 | 2803 | 0.080 |
Why?
|
| Breast Neoplasms | 6 | 2007 | 21017 | 0.080 |
Why?
|
| Retinal Degeneration | 1 | 2012 | 413 | 0.080 |
Why?
|
| Cerebral Infarction | 1 | 2013 | 983 | 0.080 |
Why?
|
| Fibrinolytic Agents | 1 | 2018 | 2084 | 0.080 |
Why?
|
| Renal Insufficiency | 1 | 2014 | 809 | 0.080 |
Why?
|
| Cerebral Angiography | 1 | 2014 | 1281 | 0.080 |
Why?
|
| Disease-Free Survival | 7 | 2014 | 6815 | 0.080 |
Why?
|
| Seizures | 1 | 2021 | 2957 | 0.080 |
Why?
|
| Apolipoprotein E3 | 2 | 2021 | 107 | 0.080 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 2373 | 0.080 |
Why?
|
| Acetylglucosaminidase | 1 | 2007 | 66 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 7 | 2007 | 6075 | 0.080 |
Why?
|
| Recombination, Genetic | 1 | 2013 | 1519 | 0.070 |
Why?
|
| Cell Adhesion Molecules | 1 | 2014 | 1601 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2006 | 2456 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2011 | 571 | 0.070 |
Why?
|
| Papillomaviridae | 2 | 2004 | 1119 | 0.070 |
Why?
|
| Natural Language Processing | 1 | 2016 | 1163 | 0.070 |
Why?
|
| Cerebrovascular Circulation | 1 | 2018 | 2727 | 0.070 |
Why?
|
| Mothers | 1 | 2018 | 2198 | 0.070 |
Why?
|
| Genes, Neoplasm | 1 | 2009 | 370 | 0.070 |
Why?
|
| Drainage | 1 | 2013 | 1157 | 0.070 |
Why?
|
| False Negative Reactions | 2 | 2013 | 573 | 0.070 |
Why?
|
| Topotecan | 1 | 2007 | 132 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2022 | 12148 | 0.070 |
Why?
|
| Radiopharmaceuticals | 1 | 2017 | 2651 | 0.070 |
Why?
|
| Sputum | 2 | 1999 | 506 | 0.070 |
Why?
|
| Heat-Shock Proteins | 1 | 2011 | 795 | 0.070 |
Why?
|
| Life Tables | 1 | 2007 | 364 | 0.070 |
Why?
|
| Histological Techniques | 1 | 2007 | 193 | 0.070 |
Why?
|
| Cranial Nerve Neoplasms | 1 | 2008 | 134 | 0.070 |
Why?
|
| Dipeptides | 1 | 2009 | 391 | 0.070 |
Why?
|
| Tacrolimus | 1 | 2010 | 733 | 0.070 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2018 | 2791 | 0.070 |
Why?
|
| Hospital Shared Services | 1 | 2006 | 16 | 0.070 |
Why?
|
| Atrophy | 4 | 2016 | 1633 | 0.070 |
Why?
|
| Retinal Ganglion Cells | 1 | 2012 | 811 | 0.070 |
Why?
|
| Presenilin-1 | 3 | 2019 | 660 | 0.070 |
Why?
|
| Gene Frequency | 4 | 2018 | 3606 | 0.070 |
Why?
|
| Depressive Disorder, Major | 1 | 2024 | 4761 | 0.070 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2008 | 459 | 0.070 |
Why?
|
| DNA-Binding Proteins | 5 | 2008 | 9610 | 0.070 |
Why?
|
| Life Style | 1 | 2018 | 3917 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 8 | 2019 | 22172 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2004 | 698 | 0.070 |
Why?
|
| Gene Order | 1 | 2006 | 169 | 0.070 |
Why?
|
| Telephone | 1 | 2009 | 627 | 0.070 |
Why?
|
| Interferon-beta | 1 | 2008 | 345 | 0.070 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2012 | 1141 | 0.070 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 1 | 2008 | 254 | 0.070 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2006 | 203 | 0.060 |
Why?
|
| Child | 12 | 2024 | 80156 | 0.060 |
Why?
|
| Aneuploidy | 1 | 2009 | 552 | 0.060 |
Why?
|
| Mood Disorders | 2 | 2004 | 1127 | 0.060 |
Why?
|
| Twins, Dizygotic | 2 | 2009 | 236 | 0.060 |
Why?
|
| Severity of Illness Index | 5 | 2021 | 15843 | 0.060 |
Why?
|
| Transfection | 1 | 2013 | 5774 | 0.060 |
Why?
|
| Databases, Factual | 3 | 2020 | 7967 | 0.060 |
Why?
|
| Tumor Microenvironment | 1 | 2018 | 3877 | 0.060 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2013 | 6019 | 0.060 |
Why?
|
| Neuroma, Acoustic | 1 | 2009 | 459 | 0.060 |
Why?
|
| Protease Inhibitors | 1 | 2009 | 754 | 0.060 |
Why?
|
| Precancerous Conditions | 1 | 2012 | 980 | 0.060 |
Why?
|
| Erythrocytes | 1 | 2014 | 2413 | 0.060 |
Why?
|
| Ependymoma | 1 | 2008 | 320 | 0.060 |
Why?
|
| Astrocytoma | 2 | 2006 | 775 | 0.060 |
Why?
|
| Antineoplastic Agents | 5 | 2017 | 13642 | 0.060 |
Why?
|
| Dopamine | 1 | 2012 | 1607 | 0.060 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2005 | 186 | 0.060 |
Why?
|
| Nerve Tissue Proteins | 2 | 2012 | 4415 | 0.060 |
Why?
|
| Protein Sorting Signals | 1 | 2005 | 279 | 0.060 |
Why?
|
| Esophagectomy | 2 | 2006 | 468 | 0.060 |
Why?
|
| Transcription Factors | 4 | 2011 | 12129 | 0.060 |
Why?
|
| Receptors, Cholinergic | 1 | 2005 | 244 | 0.060 |
Why?
|
| Celiac Disease | 1 | 2013 | 821 | 0.060 |
Why?
|
| Interviews as Topic | 1 | 2012 | 2696 | 0.060 |
Why?
|
| Receptors, Growth Factor | 1 | 2005 | 326 | 0.060 |
Why?
|
| Axons | 1 | 2012 | 1674 | 0.060 |
Why?
|
| Immunization, Passive | 1 | 2007 | 616 | 0.060 |
Why?
|
| Ischemia | 1 | 2013 | 1883 | 0.060 |
Why?
|
| Pneumocystis carinii | 1 | 2005 | 72 | 0.060 |
Why?
|
| Tissue Array Analysis | 1 | 2006 | 550 | 0.060 |
Why?
|
| Ubiquinone | 1 | 2005 | 183 | 0.060 |
Why?
|
| Genetic Heterogeneity | 2 | 2011 | 732 | 0.060 |
Why?
|
| Evolution, Molecular | 1 | 2013 | 1886 | 0.060 |
Why?
|
| Surgery Department, Hospital | 1 | 2005 | 176 | 0.060 |
Why?
|
| Transient Receptor Potential Channels | 2 | 2015 | 130 | 0.060 |
Why?
|
| Dacarbazine | 1 | 2007 | 559 | 0.060 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 2243 | 0.060 |
Why?
|
| Feasibility Studies | 3 | 2023 | 5247 | 0.060 |
Why?
|
| Kidney Failure, Chronic | 1 | 2016 | 2472 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2014 | 11742 | 0.060 |
Why?
|
| Gene Deletion | 4 | 2005 | 2665 | 0.060 |
Why?
|
| HIV Seropositivity | 2 | 2000 | 960 | 0.060 |
Why?
|
| Chromosomes, Human | 1 | 2006 | 441 | 0.060 |
Why?
|
| Artifacts | 1 | 2012 | 1911 | 0.060 |
Why?
|
| Pandemics | 2 | 2021 | 8656 | 0.060 |
Why?
|
| Melanoma | 1 | 2022 | 5709 | 0.060 |
Why?
|
| Myocardial Infarction | 2 | 2022 | 11461 | 0.060 |
Why?
|
| Perineum | 1 | 2005 | 208 | 0.050 |
Why?
|
| Anxiety | 1 | 2018 | 4573 | 0.050 |
Why?
|
| Immunophenotyping | 2 | 2018 | 1869 | 0.050 |
Why?
|
| Cross-Sectional Studies | 6 | 2024 | 26127 | 0.050 |
Why?
|
| Genetic Testing | 2 | 2014 | 3537 | 0.050 |
Why?
|
| Risk Assessment | 3 | 2018 | 23996 | 0.050 |
Why?
|
| Eye Neoplasms | 1 | 2005 | 307 | 0.050 |
Why?
|
| Body Mass Index | 2 | 2020 | 12954 | 0.050 |
Why?
|
| Vitreous Body | 1 | 2005 | 399 | 0.050 |
Why?
|
| Keratosis, Seborrheic | 1 | 2003 | 27 | 0.050 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2005 | 726 | 0.050 |
Why?
|
| Nuclear Family | 1 | 2004 | 311 | 0.050 |
Why?
|
| Anti-HIV Agents | 5 | 2000 | 4527 | 0.050 |
Why?
|
| Feces | 2 | 1999 | 1497 | 0.050 |
Why?
|
| Immunoglobulins | 1 | 2006 | 852 | 0.050 |
Why?
|
| Surgical Procedures, Operative | 2 | 2005 | 1924 | 0.050 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2006 | 333 | 0.050 |
Why?
|
| Dementia, Multi-Infarct | 1 | 2002 | 10 | 0.050 |
Why?
|
| Psychotic Disorders | 1 | 2018 | 3223 | 0.050 |
Why?
|
| Vulvar Diseases | 1 | 2003 | 64 | 0.050 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2008 | 727 | 0.050 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2024 | 84 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3086 | 0.050 |
Why?
|
| Oligodendroglia | 1 | 2006 | 538 | 0.050 |
Why?
|
| Gene Amplification | 2 | 2005 | 1089 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3206 | 0.050 |
Why?
|
| Homeostasis | 1 | 2013 | 3323 | 0.050 |
Why?
|
| Quality of Life | 1 | 2024 | 13367 | 0.050 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2006 | 531 | 0.050 |
Why?
|
| Patient Transfer | 1 | 2009 | 794 | 0.050 |
Why?
|
| STAT3 Transcription Factor | 1 | 2006 | 871 | 0.050 |
Why?
|
| Maternal Age | 1 | 2005 | 809 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2006 | 1062 | 0.050 |
Why?
|
| Uterine Neoplasms | 1 | 2011 | 1420 | 0.050 |
Why?
|
| Enzyme Activation | 4 | 2012 | 3597 | 0.050 |
Why?
|
| Philosophy | 1 | 2002 | 68 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2014 | 20571 | 0.050 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2003 | 133 | 0.050 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2003 | 170 | 0.050 |
Why?
|
| Hearing Loss | 1 | 2009 | 783 | 0.050 |
Why?
|
| Papillomavirus Infections | 2 | 2004 | 1613 | 0.050 |
Why?
|
| Live Birth | 1 | 2005 | 511 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2006 | 1246 | 0.050 |
Why?
|
| Hospitals, University | 1 | 2003 | 564 | 0.050 |
Why?
|
| Factor VII | 1 | 2002 | 139 | 0.050 |
Why?
|
| Cause of Death | 1 | 2012 | 3683 | 0.050 |
Why?
|
| Retina | 1 | 2012 | 2659 | 0.050 |
Why?
|
| Ovarian Neoplasms | 2 | 2011 | 4878 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2006 | 1642 | 0.050 |
Why?
|
| Ventilators, Mechanical | 1 | 2023 | 288 | 0.050 |
Why?
|
| Selection Bias | 1 | 2003 | 359 | 0.050 |
Why?
|
| Ferritins | 1 | 2024 | 598 | 0.050 |
Why?
|
| Integrins | 1 | 2005 | 834 | 0.050 |
Why?
|
| Adenosine Diphosphate | 1 | 2022 | 422 | 0.050 |
Why?
|
| Pokeweed Mitogens | 1 | 2000 | 38 | 0.050 |
Why?
|
| Sulfonylurea Compounds | 1 | 2022 | 219 | 0.050 |
Why?
|
| Neurofibromin 1 | 1 | 2022 | 190 | 0.050 |
Why?
|
| Anus Neoplasms | 1 | 2005 | 329 | 0.050 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 3688 | 0.050 |
Why?
|
| DNA Probes | 2 | 2012 | 541 | 0.050 |
Why?
|
| Glycoproteins | 2 | 2006 | 2203 | 0.050 |
Why?
|
| Infarction | 1 | 2022 | 248 | 0.050 |
Why?
|
| Antiviral Agents | 2 | 2021 | 3060 | 0.050 |
Why?
|
| Diagnosis, Differential | 7 | 2013 | 12975 | 0.040 |
Why?
|
| Fibrinogen | 1 | 2024 | 888 | 0.040 |
Why?
|
| Drug Repositioning | 1 | 2022 | 233 | 0.040 |
Why?
|
| Streptokinase | 1 | 2000 | 186 | 0.040 |
Why?
|
| Calcium | 1 | 2013 | 5722 | 0.040 |
Why?
|
| Tumor Virus Infections | 1 | 2003 | 438 | 0.040 |
Why?
|
| Age Factors | 6 | 2018 | 18398 | 0.040 |
Why?
|
| Gene Rearrangement | 1 | 2005 | 1125 | 0.040 |
Why?
|
| Neoplasms, Second Primary | 1 | 2008 | 1052 | 0.040 |
Why?
|
| Tetanus Toxoid | 1 | 2000 | 189 | 0.040 |
Why?
|
| Diet | 1 | 2018 | 8075 | 0.040 |
Why?
|
| Signal Transduction | 5 | 2012 | 23447 | 0.040 |
Why?
|
| Compensation and Redress | 1 | 2020 | 66 | 0.040 |
Why?
|
| ROC Curve | 3 | 2013 | 3579 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2015 | 3429 | 0.040 |
Why?
|
| Candida | 1 | 2000 | 172 | 0.040 |
Why?
|
| Zidovudine | 2 | 2000 | 624 | 0.040 |
Why?
|
| Point Mutation | 1 | 2004 | 1595 | 0.040 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2002 | 621 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2009 | 4575 | 0.040 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2001 | 412 | 0.040 |
Why?
|
| Radionuclide Imaging | 2 | 2014 | 1972 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2016 | 4811 | 0.040 |
Why?
|
| Child, Preschool | 6 | 2021 | 42230 | 0.040 |
Why?
|
| Neuroprotective Agents | 1 | 2005 | 957 | 0.040 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2000 | 269 | 0.040 |
Why?
|
| DNA Mutational Analysis | 4 | 2012 | 4111 | 0.040 |
Why?
|
| Cerebellar Neoplasms | 1 | 2004 | 586 | 0.040 |
Why?
|
| Body Temperature | 1 | 2022 | 781 | 0.040 |
Why?
|
| Platelet Aggregation | 1 | 2022 | 771 | 0.040 |
Why?
|
| Transportation | 1 | 2000 | 217 | 0.040 |
Why?
|
| Cell Division | 3 | 2001 | 4465 | 0.040 |
Why?
|
| Hemorrhage | 2 | 2014 | 3424 | 0.040 |
Why?
|
| Bone and Bones | 1 | 2009 | 2568 | 0.040 |
Why?
|
| Abdomen | 1 | 2005 | 1128 | 0.040 |
Why?
|
| Glial Fibrillary Acidic Protein | 3 | 2006 | 553 | 0.040 |
Why?
|
| Medulloblastoma | 1 | 2004 | 678 | 0.040 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2000 | 416 | 0.040 |
Why?
|
| Molecular Biology | 1 | 2002 | 576 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2005 | 1336 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 2 | 2014 | 883 | 0.040 |
Why?
|
| Liability, Legal | 1 | 2020 | 210 | 0.040 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2005 | 1626 | 0.040 |
Why?
|
| Estradiol | 1 | 2005 | 1937 | 0.040 |
Why?
|
| Esthetics | 1 | 2000 | 330 | 0.040 |
Why?
|
| Neopterin | 1 | 1997 | 56 | 0.040 |
Why?
|
| Genetics, Medical | 1 | 2001 | 334 | 0.040 |
Why?
|
| Didanosine | 1 | 1998 | 151 | 0.040 |
Why?
|
| Genome | 1 | 2006 | 1740 | 0.040 |
Why?
|
| Calcium-Binding Proteins | 3 | 2013 | 1069 | 0.040 |
Why?
|
| Proteinuria | 1 | 2001 | 607 | 0.040 |
Why?
|
| Benzene Derivatives | 2 | 2009 | 53 | 0.040 |
Why?
|
| Dialysis Solutions | 1 | 1997 | 33 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2009 | 3113 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2005 | 12341 | 0.040 |
Why?
|
| Population Surveillance | 2 | 2003 | 2598 | 0.040 |
Why?
|
| Ultrafiltration | 1 | 1997 | 49 | 0.040 |
Why?
|
| Alkenes | 2 | 2009 | 54 | 0.040 |
Why?
|
| Population Growth | 1 | 1997 | 50 | 0.040 |
Why?
|
| Cell Lineage | 1 | 2006 | 2556 | 0.040 |
Why?
|
| Transcriptional Activation | 2 | 2018 | 1756 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2013 | 3816 | 0.040 |
Why?
|
| Mucous Membrane | 1 | 2021 | 659 | 0.040 |
Why?
|
| Fertilization in Vitro | 1 | 2005 | 1292 | 0.040 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 1999 | 220 | 0.040 |
Why?
|
| Thiones | 1 | 2017 | 46 | 0.040 |
Why?
|
| Receptors, IgE | 1 | 1999 | 375 | 0.040 |
Why?
|
| Pyrroles | 1 | 2023 | 1125 | 0.040 |
Why?
|
| Organizational Innovation | 1 | 2020 | 537 | 0.040 |
Why?
|
| Blood Specimen Collection | 1 | 1998 | 238 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2014 | 7858 | 0.040 |
Why?
|
| Medical Records | 1 | 2022 | 1408 | 0.040 |
Why?
|
| Quality Indicators, Health Care | 2 | 2005 | 1792 | 0.040 |
Why?
|
| Palmitates | 1 | 2017 | 70 | 0.030 |
Why?
|
| Photic Stimulation | 2 | 2014 | 1987 | 0.030 |
Why?
|
| Propranolol | 1 | 1998 | 489 | 0.030 |
Why?
|
| Hemodiafiltration | 1 | 2016 | 18 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 1999 | 778 | 0.030 |
Why?
|
| Stilbenes | 2 | 2009 | 155 | 0.030 |
Why?
|
| Area Under Curve | 2 | 2012 | 1638 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2004 | 2917 | 0.030 |
Why?
|
| Evoked Potentials, Visual | 1 | 2019 | 417 | 0.030 |
Why?
|
| Genetic Vectors | 2 | 2018 | 3396 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2005 | 3687 | 0.030 |
Why?
|
| Stochastic Processes | 1 | 1997 | 355 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2002 | 1596 | 0.030 |
Why?
|
| Hospitalization | 2 | 2013 | 10721 | 0.030 |
Why?
|
| Receptors, Cell Surface | 2 | 2002 | 2822 | 0.030 |
Why?
|
| Recurrence | 1 | 2008 | 8466 | 0.030 |
Why?
|
| Disease | 1 | 2001 | 672 | 0.030 |
Why?
|
| Immunoglobulin A | 1 | 1999 | 978 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2009 | 4513 | 0.030 |
Why?
|
| Sarcoma | 1 | 2006 | 1801 | 0.030 |
Why?
|
| Carcinoma, Small Cell | 1 | 1997 | 420 | 0.030 |
Why?
|
| Triage | 1 | 2022 | 986 | 0.030 |
Why?
|
| Microdissection | 2 | 2005 | 151 | 0.030 |
Why?
|
| RNA, Messenger | 4 | 2018 | 12794 | 0.030 |
Why?
|
| Entorhinal Cortex | 1 | 2016 | 287 | 0.030 |
Why?
|
| Partial Pressure | 1 | 2014 | 245 | 0.030 |
Why?
|
| Urine | 1 | 2016 | 362 | 0.030 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2005 | 1469 | 0.030 |
Why?
|
| Lameness, Animal | 1 | 2014 | 7 | 0.030 |
Why?
|
| Thymus Gland | 1 | 1999 | 1243 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 1997 | 1624 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2015 | 613 | 0.030 |
Why?
|
| Infant | 4 | 2021 | 36192 | 0.030 |
Why?
|
| Calcium Sulfate | 1 | 2014 | 24 | 0.030 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2016 | 395 | 0.030 |
Why?
|
| Coronary Artery Bypass | 1 | 2003 | 2188 | 0.030 |
Why?
|
| Spirometry | 1 | 1997 | 929 | 0.030 |
Why?
|
| Prostatic Neoplasms | 2 | 2000 | 11122 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2015 | 10766 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 2006 | 4431 | 0.030 |
Why?
|
| Oxyhemoglobins | 1 | 2014 | 211 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2017 | 588 | 0.030 |
Why?
|
| Neurites | 1 | 2015 | 391 | 0.030 |
Why?
|
| Injections, Intraventricular | 1 | 2013 | 225 | 0.030 |
Why?
|
| Dental Materials | 1 | 2014 | 113 | 0.030 |
Why?
|
| Electroretinography | 1 | 2015 | 525 | 0.030 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2014 | 174 | 0.030 |
Why?
|
| Mental Status Schedule | 1 | 2014 | 315 | 0.030 |
Why?
|
| Massachusetts | 2 | 2019 | 8830 | 0.030 |
Why?
|
| Neoplasm Proteins | 2 | 2005 | 3617 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2008 | 8552 | 0.030 |
Why?
|
| Exploratory Behavior | 1 | 2014 | 279 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2006 | 3600 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2018 | 1626 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2019 | 1188 | 0.030 |
Why?
|
| Task Performance and Analysis | 1 | 2017 | 763 | 0.030 |
Why?
|
| Vesicular Inhibitory Amino Acid Transport Proteins | 1 | 2012 | 43 | 0.030 |
Why?
|
| Antibodies, Bacterial | 1 | 1999 | 1469 | 0.030 |
Why?
|
| Nephrology | 1 | 2016 | 263 | 0.030 |
Why?
|
| Patient Preference | 1 | 2020 | 924 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2001 | 1902 | 0.030 |
Why?
|
| Vesicular Monoamine Transport Proteins | 1 | 2012 | 32 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2015 | 5035 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1998 | 1241 | 0.030 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2000 | 1935 | 0.030 |
Why?
|
| DNA Repair Enzymes | 2 | 2007 | 346 | 0.030 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2012 | 317 | 0.030 |
Why?
|
| Metabolome | 1 | 2019 | 989 | 0.030 |
Why?
|
| Maze Learning | 1 | 2014 | 483 | 0.030 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2012 | 87 | 0.030 |
Why?
|
| DNA, Viral | 2 | 2013 | 2202 | 0.030 |
Why?
|
| Netherlands | 1 | 2017 | 2221 | 0.030 |
Why?
|
| Telemedicine | 1 | 2009 | 3052 | 0.020 |
Why?
|
| Parents | 1 | 2006 | 3563 | 0.020 |
Why?
|
| Evoked Potentials | 1 | 2018 | 1047 | 0.020 |
Why?
|
| Sex Factors | 2 | 2018 | 10553 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1999 | 1802 | 0.020 |
Why?
|
| Chromosomes, Human, Y | 1 | 2012 | 161 | 0.020 |
Why?
|
| Forecasting | 1 | 2020 | 2928 | 0.020 |
Why?
|
| Luminescent Proteins | 1 | 2014 | 837 | 0.020 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2012 | 370 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2015 | 2468 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 12690 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 2 | 2005 | 1705 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2013 | 957 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2017 | 1971 | 0.020 |
Why?
|
| GPI-Linked Proteins | 1 | 2012 | 470 | 0.020 |
Why?
|
| Intravitreal Injections | 1 | 2012 | 385 | 0.020 |
Why?
|
| Solubility | 1 | 2012 | 1091 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2012 | 695 | 0.020 |
Why?
|
| Chromosomes, Human, X | 1 | 2012 | 321 | 0.020 |
Why?
|
| Educational Status | 1 | 2018 | 2522 | 0.020 |
Why?
|
| Myelin Sheath | 1 | 2014 | 653 | 0.020 |
Why?
|
| RNA, Viral | 1 | 1999 | 2846 | 0.020 |
Why?
|
| Microsatellite Repeats | 1 | 2012 | 784 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 3514 | 0.020 |
Why?
|
| Patch-Clamp Techniques | 1 | 2012 | 927 | 0.020 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2005 | 2422 | 0.020 |
Why?
|
| Frozen Sections | 1 | 2010 | 153 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2014 | 2496 | 0.020 |
Why?
|
| Capillaries | 1 | 2013 | 755 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2022 | 3085 | 0.020 |
Why?
|
| Multifactorial Inheritance | 1 | 2018 | 1387 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2012 | 903 | 0.020 |
Why?
|
| Mice, Knockout | 2 | 2015 | 14416 | 0.020 |
Why?
|
| Registries | 1 | 2006 | 8224 | 0.020 |
Why?
|
| Fluorescent Dyes | 2 | 2009 | 1903 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 2012 | 864 | 0.020 |
Why?
|
| Flow Cytometry | 3 | 2006 | 5869 | 0.020 |
Why?
|
| Cyclic N-Oxides | 1 | 2009 | 72 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2008 | 1406 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2012 | 1090 | 0.020 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2012 | 455 | 0.020 |
Why?
|
| Transgenes | 1 | 2012 | 1010 | 0.020 |
Why?
|
| Thrombolytic Therapy | 1 | 2018 | 2064 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2017 | 4063 | 0.020 |
Why?
|
| Overweight | 1 | 2020 | 2417 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2018 | 2547 | 0.020 |
Why?
|
| Lipocalins | 1 | 2009 | 161 | 0.020 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2012 | 542 | 0.020 |
Why?
|
| Models, Theoretical | 2 | 2009 | 3575 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2018 | 11904 | 0.020 |
Why?
|
| Acute-Phase Proteins | 1 | 2009 | 250 | 0.020 |
Why?
|
| Arterioles | 1 | 2009 | 250 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2009 | 322 | 0.020 |
Why?
|
| Nerve Fibers | 1 | 2012 | 708 | 0.020 |
Why?
|
| Quinazolines | 1 | 2014 | 1371 | 0.020 |
Why?
|
| Pattern Recognition, Automated | 1 | 2014 | 997 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2001 | 4937 | 0.020 |
Why?
|
| Brain Stem | 1 | 2013 | 858 | 0.020 |
Why?
|
| Temporal Lobe | 1 | 2015 | 1695 | 0.020 |
Why?
|
| Neural Inhibition | 1 | 2012 | 590 | 0.020 |
Why?
|
| Minocycline | 1 | 2009 | 169 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2012 | 1687 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 1998 | 5485 | 0.020 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2012 | 604 | 0.020 |
Why?
|
| Sirolimus | 1 | 2014 | 1533 | 0.020 |
Why?
|
| Dependovirus | 1 | 2012 | 718 | 0.020 |
Why?
|
| Neocortex | 1 | 2011 | 417 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2014 | 2919 | 0.020 |
Why?
|
| Biomedical Engineering | 1 | 2009 | 288 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2012 | 1736 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2020 | 8633 | 0.020 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2011 | 369 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2012 | 2065 | 0.020 |
Why?
|
| Diabetic Nephropathies | 1 | 2014 | 973 | 0.020 |
Why?
|
| Remote Consultation | 1 | 2009 | 237 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2020 | 3744 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 1999 | 4544 | 0.020 |
Why?
|
| Neurofibromin 2 | 1 | 2008 | 270 | 0.020 |
Why?
|
| Mice, Neurologic Mutants | 1 | 2006 | 107 | 0.020 |
Why?
|
| Electromyography | 1 | 2012 | 1394 | 0.020 |
Why?
|
| Brain Concussion | 1 | 2018 | 1404 | 0.020 |
Why?
|
| Cerebral Arteries | 1 | 2009 | 490 | 0.020 |
Why?
|
| Molecular Imaging | 1 | 2013 | 815 | 0.020 |
Why?
|
| Simvastatin | 1 | 2009 | 346 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 2006 | 6935 | 0.020 |
Why?
|
| Matrix Metalloproteinases | 1 | 2009 | 393 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 3889 | 0.020 |
Why?
|
| Skin Window Technique | 1 | 2006 | 22 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2012 | 1187 | 0.020 |
Why?
|
| Computational Biology | 1 | 2018 | 3517 | 0.020 |
Why?
|
| DNA Modification Methylases | 1 | 2007 | 210 | 0.020 |
Why?
|
| Cerebellum | 1 | 2013 | 1501 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 5672 | 0.020 |
Why?
|
| Paxillin | 1 | 2005 | 86 | 0.020 |
Why?
|
| Neuronal Plasticity | 1 | 2014 | 1436 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2018 | 5112 | 0.020 |
Why?
|
| Incidence | 2 | 2016 | 21355 | 0.020 |
Why?
|
| Dental Implants | 1 | 2014 | 795 | 0.020 |
Why?
|
| Coenzymes | 1 | 2005 | 102 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 6534 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 1999 | 4758 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2006 | 384 | 0.020 |
Why?
|
| Integrin beta Chains | 1 | 2005 | 115 | 0.020 |
Why?
|
| Contrast Media | 1 | 2018 | 5311 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2006 | 510 | 0.020 |
Why?
|
| Hearing | 1 | 2009 | 501 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2018 | 3359 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2014 | 6214 | 0.020 |
Why?
|
| Phylogeny | 1 | 2013 | 2811 | 0.020 |
Why?
|
| Cholesterol | 1 | 2014 | 2904 | 0.020 |
Why?
|
| Genes, erbB-1 | 1 | 2005 | 162 | 0.020 |
Why?
|
| Free Radical Scavengers | 1 | 2005 | 211 | 0.020 |
Why?
|
| Genes, p16 | 1 | 2005 | 160 | 0.020 |
Why?
|
| Postmortem Changes | 1 | 2004 | 119 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2009 | 2218 | 0.010 |
Why?
|
| Protein Structure, Quaternary | 1 | 2005 | 429 | 0.010 |
Why?
|
| Genes, Immunoglobulin | 1 | 2005 | 285 | 0.010 |
Why?
|
| Congenital Abnormalities | 1 | 2009 | 709 | 0.010 |
Why?
|
| Motor Activity | 1 | 2014 | 2715 | 0.010 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2005 | 419 | 0.010 |
Why?
|
| Inflammation | 1 | 2024 | 10773 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2005 | 473 | 0.010 |
Why?
|
| Meninges | 1 | 2006 | 198 | 0.010 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2018 | 3080 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 2005 | 367 | 0.010 |
Why?
|
| DNA | 2 | 2009 | 7213 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2004 | 329 | 0.010 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 2811 | 0.010 |
Why?
|
| Longevity | 1 | 2011 | 1065 | 0.010 |
Why?
|
| Syndecans | 1 | 2003 | 75 | 0.010 |
Why?
|
| Neural Pathways | 1 | 2014 | 3060 | 0.010 |
Why?
|
| Oxygen | 1 | 2014 | 4227 | 0.010 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2005 | 615 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2014 | 8181 | 0.010 |
Why?
|
| Genes, p53 | 1 | 2005 | 712 | 0.010 |
Why?
|
| Cyclin E | 1 | 2003 | 156 | 0.010 |
Why?
|
| Early Diagnosis | 1 | 2007 | 1186 | 0.010 |
Why?
|
| HEK293 Cells | 1 | 2012 | 4280 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2003 | 191 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2006 | 2264 | 0.010 |
Why?
|
| Vindesine | 1 | 2002 | 12 | 0.010 |
Why?
|
| Tomography, Optical Coherence | 1 | 2015 | 2917 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2022 | 7879 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2005 | 15633 | 0.010 |
Why?
|
| Cold Temperature | 1 | 2006 | 785 | 0.010 |
Why?
|
| Syndecan-1 | 1 | 2003 | 163 | 0.010 |
Why?
|
| Vitrectomy | 1 | 2005 | 392 | 0.010 |
Why?
|
| Drug Administration Schedule | 2 | 2007 | 4853 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2003 | 767 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2018 | 18965 | 0.010 |
Why?
|
| Vasodilation | 1 | 2006 | 962 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 2005 | 13446 | 0.010 |
Why?
|
| Cranial Irradiation | 1 | 2004 | 390 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 7407 | 0.010 |
Why?
|
| Synucleins | 1 | 2001 | 108 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1991 | 2827 | 0.010 |
Why?
|
| Colombia | 1 | 2002 | 282 | 0.010 |
Why?
|
| Interferon Regulatory Factors | 1 | 2003 | 261 | 0.010 |
Why?
|
| Vaginal Smears | 1 | 2004 | 499 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 2002 | 777 | 0.010 |
Why?
|
| HIV-1 | 1 | 1999 | 6863 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2005 | 2180 | 0.010 |
Why?
|
| Oleic Acid | 1 | 2001 | 92 | 0.010 |
Why?
|
| Craniotomy | 1 | 2006 | 741 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2009 | 2141 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 2003 | 629 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 2005 | 17635 | 0.010 |
Why?
|
| Internet | 1 | 2013 | 3093 | 0.010 |
Why?
|
| Zalcitabine | 1 | 2000 | 43 | 0.010 |
Why?
|
| Cell Count | 1 | 2004 | 1835 | 0.010 |
Why?
|
| Autoantigens | 1 | 2005 | 891 | 0.010 |
Why?
|
| Cervix Uteri | 1 | 2004 | 570 | 0.010 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2006 | 1136 | 0.010 |
Why?
|
| Base Sequence | 1 | 2011 | 12441 | 0.010 |
Why?
|
| Zebrafish Proteins | 1 | 2006 | 1014 | 0.010 |
Why?
|
| Neprilysin | 1 | 2003 | 478 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2003 | 803 | 0.010 |
Why?
|
| Xenobiotics | 1 | 1999 | 70 | 0.010 |
Why?
|
| Cell Line | 2 | 2005 | 15601 | 0.010 |
Why?
|
| Length of Stay | 1 | 2013 | 6426 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2006 | 2898 | 0.010 |
Why?
|
| Internship and Residency | 1 | 2020 | 5882 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2014 | 3415 | 0.010 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2001 | 296 | 0.010 |
Why?
|
| RNA | 1 | 2009 | 2726 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2004 | 4174 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2014 | 6567 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 1999 | 427 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2012 | 5972 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2001 | 2186 | 0.010 |
Why?
|
| DNA Primers | 1 | 2003 | 2819 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2005 | 3792 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1999 | 26198 | 0.010 |
Why?
|
| Arginine | 1 | 2002 | 934 | 0.010 |
Why?
|
| Remission Induction | 1 | 2004 | 2397 | 0.010 |
Why?
|
| Mitogens | 1 | 1998 | 230 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2013 | 6391 | 0.010 |
Why?
|
| Cytosol | 1 | 2001 | 888 | 0.010 |
Why?
|
| Endarterectomy, Carotid | 1 | 2003 | 555 | 0.010 |
Why?
|
| Kinetics | 1 | 2006 | 6374 | 0.010 |
Why?
|
| Age Distribution | 1 | 2004 | 2880 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 2005 | 1315 | 0.010 |
Why?
|
| Obesity | 1 | 2020 | 12947 | 0.010 |
Why?
|
| Cysteine | 1 | 2002 | 891 | 0.010 |
Why?
|
| Organ Culture Techniques | 1 | 1999 | 794 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2006 | 2416 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2005 | 3733 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2001 | 2748 | 0.010 |
Why?
|
| Brain Mapping | 1 | 2012 | 6635 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 3713 | 0.010 |
Why?
|
| Body Weight | 1 | 1987 | 4618 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2005 | 6228 | 0.010 |
Why?
|
| Gene Expression | 1 | 2009 | 7581 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2005 | 4124 | 0.010 |
Why?
|
| Phenotype | 1 | 2014 | 16592 | 0.010 |
Why?
|
| Homozygote | 1 | 2001 | 1776 | 0.010 |
Why?
|
| Rectal Neoplasms | 1 | 2005 | 1157 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2002 | 2220 | 0.010 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1999 | 547 | 0.010 |
Why?
|
| DNA Helicases | 1 | 2001 | 851 | 0.010 |
Why?
|
| Cisplatin | 1 | 2002 | 1652 | 0.010 |
Why?
|
| Heterozygote | 1 | 2002 | 2787 | 0.010 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2001 | 1115 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2005 | 4141 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 2005 | 2169 | 0.010 |
Why?
|
| alpha-Synuclein | 1 | 2001 | 750 | 0.010 |
Why?
|
| Vascular Surgical Procedures | 1 | 2003 | 1489 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 2005 | 2882 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2006 | 8528 | 0.010 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 3245 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 16986 | 0.010 |
Why?
|
| Cell Differentiation | 2 | 2003 | 11530 | 0.010 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2003 | 1228 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2006 | 2781 | 0.010 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2003 | 1405 | 0.010 |
Why?
|
| Cell Separation | 1 | 1998 | 1720 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2001 | 4615 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1997 | 13382 | 0.010 |
Why?
|
| Mitochondria | 1 | 2005 | 3624 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2006 | 3963 | 0.010 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2004 | 2020 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2006 | 5799 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1998 | 1844 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2007 | 10448 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2005 | 9319 | 0.010 |
Why?
|
| Lipids | 1 | 2001 | 3341 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2000 | 6312 | 0.010 |
Why?
|
| Rats | 1 | 2005 | 23741 | 0.010 |
Why?
|
| Pregnancy | 1 | 2011 | 29876 | 0.010 |
Why?
|
| Protein Binding | 1 | 2001 | 9353 | 0.010 |
Why?
|
| Body Surface Area | 1 | 1987 | 197 | 0.000 |
Why?
|
| Anticoagulants | 1 | 1998 | 4812 | 0.000 |
Why?
|
| Body Height | 1 | 1987 | 1570 | 0.000 |
Why?
|